Εμφάνιση απλής εγγραφής

dc.creatorMelissaropoulos K., Bogdanos D., Dimitroulas T., Sakkas L.I., Kitas G.D., Daoussis D.en
dc.date.accessioned2023-01-31T08:58:43Z
dc.date.available2023-01-31T08:58:43Z
dc.date.issued2020
dc.identifier10.2174/1570161118666200129125320
dc.identifier.issn15701611
dc.identifier.urihttp://hdl.handle.net/11615/76499
dc.description.abstractSjögren’s syndrome is a rheumatic autoimmune disease that primarily affects middle-aged women and runs a slowly progressing course with sicca symptoms being the prevalent manifestation. Premature atherosclerosis and increased cardiovascular (CV) morbidity and mortality are frequently encountered in rheumatic diseases characterized by significant systemic inflammation, such as the inflammatory arthritides, systemic vasculitides and systemic lupus erythematosus. In the same context, chronic inflammation and immune aberrations underlying Sjögren’s syndrome are also reported to be associated with augmented risk of atherosclerosis. Increased CV disease (CVD) frequency has been found in recent meta-analyses. The involvement of the CV system is not a common feature of Sjögren’s0 syndrome; however, specific manifestations, such as autoantibody-mediated heart block, pericarditis, pulmonary arterial hypertension and dysautonomia, have been described. This review focuses on studies addressing CV morbidity in Sjögren’s syndrome and presents current data regarding distinct CV fea-tures of the disease. © 2020 Bentham Science Publishers.en
dc.language.isoenen
dc.sourceCurrent Vascular Pharmacologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85089606772&doi=10.2174%2f1570161118666200129125320&partnerID=40&md5=6d2905bd01205377449b531c9d6ddb69
dc.subjectantinuclear antibodyen
dc.subjecthydroxychloroquineen
dc.subjectantirheumatic agenten
dc.subjectatherosclerosisen
dc.subjectautonomic neuropathyen
dc.subjectcardiovascular diseaseen
dc.subjectcardiovascular risken
dc.subjectdysautonomiaen
dc.subjectechocardiographyen
dc.subjectheart blocken
dc.subjecthumanen
dc.subjectinflammationen
dc.subjectmeta analysisen
dc.subjectmorbidityen
dc.subjectmortalityen
dc.subjectmyocarditisen
dc.subjectpericarditisen
dc.subjectpulmonary hypertensionen
dc.subjectquestionnaireen
dc.subjectRaynaud phenomenonen
dc.subjectReviewen
dc.subjectrisk factoren
dc.subjectSjoegren syndromeen
dc.subjectsystemic lupus erythematosusen
dc.subjectsystemic sclerosisen
dc.subjectanimalen
dc.subjectautoimmune diseaseen
dc.subjectcardiovascular diseaseen
dc.subjectcomorbidityen
dc.subjectcomplicationen
dc.subjectimmunologyen
dc.subjectinflammationen
dc.subjectpathophysiologyen
dc.subjectprognosisen
dc.subjectrisk assessmenten
dc.subjectSjoegren syndromeen
dc.subjectAnimalsen
dc.subjectAntirheumatic Agentsen
dc.subjectAutoimmune Diseasesen
dc.subjectCardiovascular Diseasesen
dc.subjectComorbidityen
dc.subjectHeart Disease Risk Factorsen
dc.subjectHumansen
dc.subjectInflammationen
dc.subjectPrognosisen
dc.subjectRisk Assessmenten
dc.subjectSjogren's Syndromeen
dc.subjectBentham Science Publishersen
dc.titlePrimary sjögren’s syndrome and cardiovascular diseaseen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής